published meta-analysis   sensitivity analysis   studies

miscellaneous in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsVERU-111, 2022 0.30 [0.14; 0.64] 0.30[0.14; 0.64]VERU-111, 202210%150NAnot evaluable death D28detailed resultsFragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80] Gunst JD, 2021 0.99 [0.29; 3.42] RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04] 0.71[0.35; 1.45]Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, RECOVERY (Aspirin), 2022364%15,285moderatenot evaluable death or transfer to ICUdetailed resultsGunst JD, 2021 0.55 [0.26; 1.17] 0.55[0.26; 1.17]Gunst JD, 202110%205NAnot evaluable deathsdetailed resultsFragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] Gunst JD, 2021 0.70 [0.20; 2.49] Nouri-Vaskeh, 2021 0.35 [0.06; 1.91] RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04] 0.62[0.32; 1.19]Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, Nouri-Vaskeh, 2021, RECOVERY (Aspirin), 2022458%15,368moderatenot evaluable deaths (time to event analysis only)detailed resultsFragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] Gunst JD, 2021 0.70 [0.20; 2.49] RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04] 0.66[0.32; 1.36]Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, RECOVERY (Aspirin), 2022366%15,288moderatenot evaluable clinical improvementdetailed resultsGunst JD, 2021 1.14 [0.83; 1.57] 1.14[0.83; 1.57]Gunst JD, 202110%208NAnot evaluable clinical improvement (time to event analysis only)detailed resultsGunst JD, 2021 1.14 [0.83; 1.57] 1.14[0.83; 1.57]Gunst JD, 202110%208NAnot evaluable death or ventilationdetailed resultsFragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96] 0.46[0.22; 0.96]Fragoso-Saavedra (PISCO), 202010%188NAnot evaluable hospital dischargedetailed resultsFragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55] RECOVERY (Aspirin), 2022 1.06 [1.02; 1.10] 1.06[1.02; 1.10]Fragoso-Saavedra (PISCO), 2020, RECOVERY (Aspirin), 202220%15,080moderatenot evaluable mechanical ventilationdetailed resultsFragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62] Gunst JD, 2021 2.27 [0.62; 8.26] 1.32[0.50; 3.45]Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021221%393moderatenot evaluable mechanical ventilation (time to event analysis only)detailed resultsFragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42] Gunst JD, 2021 0.69 [0.14; 3.42] 0.77[0.31; 1.90]Fragoso-Saavedra (PISCO), 2020, Gunst JD, 202120%396moderatenot evaluable ICU admissiondetailed resultsGunst JD, 2021 0.80 [0.34; 1.90] 0.80[0.34; 1.90]Gunst JD, 202110%205NAnot evaluable recoverydetailed resultsCrippa (CANDIDATE), 2021 0.54 [0.15; 1.94] Gunst JD, 2021 1.18 [0.87; 1.61] 1.03[0.58; 1.84]Crippa (CANDIDATE), 2021, Gunst JD, 2021226%299moderatenot evaluable serious adverse eventsdetailed resultsGunst JD, 2021 1.84 [0.79; 4.30] 1.84[0.79; 4.30]Gunst JD, 202110%205NAnot evaluable adverse eventsdetailed resultsGunst JD, 2021 0.80 [0.43; 1.51] 0.80[0.43; 1.51]Gunst JD, 202110%205NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:56 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924 - roots T: 290